Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN105 in Chinese Non-Diabetic Participants With Overweight or Obesity
NCT07803809Phase 1Recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN105 in obesity (3 cohorts), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs). Started Apr 2026; status: recruiting.
02
Drugs
MWN105
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07803809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803809.